Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Viral Hepatitis

• Publication date

  2018-07-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1111/jvh.12881PMID 29476572
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France

  2018cited by this paper
• Cost‐effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis

  2017cited by this paper
• International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement.

  2017cited by this paper
• Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany

  2017cited by this paper
• Economic impact of patients admitted to stroke units in Spain

  2017cited by this paper
• Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon‐based to direct‐acting antivirals era

  2017cited by this paper
• Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon‐based to direct‐acting antivirals era

  2017cited by this paper
• Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.

  2017cited by this paper
• An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

  2016cited by this paper
• Depression-related treatment and costs in Germany: Do they change with comorbidity? A claims data analysis.

  2016cited by this paper
• Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK

  2016cited by this paper
• Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.

  2016cited by this paper
• Sofosbuvir and Velpatasvir Combination Improves Patient‐reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis

  2016cited by this paper
• Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence

  2016cited by this paper
• Cost-Effectiveness of Sofosbuvir and Ledipasvir In The Treatment of Patients With Hepatitis C.

  2015cited by this paper
• Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

  2015cited by this paper
• Ledipasvir / Sofosbuvir for The Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups.

  2015cited by this paper
• Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain

  2015cited by this paper
• Cost-Effectiveness of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Or 4 Chronic Hepatitis C in England and Wales.

  2015cited by this paper
• Healthcare utilization of people with Type 2 diabetes in Germany: an analysis based on health insurance data

  2015cited by this paper
• What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?

  2015cited by this paper
• Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence

  2015cited by this paper
• Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?

  2015cited by this paper
• Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease

  2015cited by this paper
• Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

  2015cited by this paper
• Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

  2015cited by this paper
• The Cost of Rehumatoid Diseases In Italy: Analysis From An Italian Administrative Database.

  2015cited by this paper
• Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States

  2015cited by this paper
• Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in Spain.

  2014cited by this paper
• Costes sanitarios y no sanitarios de personas que padecen insuficiencia cardiaca crónica sintomática en España

  2014cited by this paper
• Cost of Previously Treated Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin's Lymphoma (INHL) in the United Kingdom (UK).

  2014cited by this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cited by this paper
• Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients

  2014cited by this paper
• Burden of new hospitalization for heart failure: a population‐based investigation from Italy

  2014cited by this paper
• Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis.

  2013cited by this paper
• [Rehabilitation in geriatric patients after ischemic stroke--a comparison of 2 organisational systems in Germany using claims data of a statutory health insurance fund].

  2013cited by this paper
• Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence

  2013cited by this paper
• Implications of comorbidity for primary care costs in the UK: a retrospective observational study.

  2013cited by this paper
• Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas

  2012cited by this paper
• Economic burden of patients with various etiologies of chronic systolic heart failure analyzed by resource use and costs.

  2012cited by this paper
• The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study

  2012cited by this paper
• Estimating the financial cost of chronic kidney disease to the NHS in England

  2012cited by this paper
• Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings.

  2011cited by this paper
• The health and social costs of chronic kidney disease in Italy

  2011cited by this paper
• Impact of Treatment Success on Health Service Use and Cost in Depression

  2011cited by this paper
• Cost analysis of the Spanish renal replacement therapy programme.

  2011cited by this paper
• Costs of depression in Catalonia (Spain).

  2011cited by this paper
• The costs of myocardial infarction—a longitudinal analysis using data from a large German health insurance company

  2011cited by this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2011cited by this paper
• Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3

  2011cited by this paper
• Costs of dialysis--a regional population-based analysis.

  2010cited by this paper
• Effect of Chronic Kidney Disease and Comorbid Conditions on Health Care Costs: A 10-Year Observational Study in a General Population

  2009cited by this paper
• Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome.

  2007cited by this paper
• Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.

  2002cited by this paper
• Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C.

  2002cited by this paper
• Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.

  1999cited by this paper
• Extrahepatic manifestations of chronic hepatitis C

  1999cited by this paper
• Clinicoeconomics and Outcomes Research

  year unknowncited by this paper

• Sicca manifestations and lymphoproliferation in hepatitis C virus: effects of direct acting antiviral therapy on dryness and B-cell activity compared to Sjögren’s disease

  2025cites this paper
• Value of public health interventions for HIV, HBV and HCV integrated screening: The FOCUS-CRIVALVIR programme.

  2025cites this paper
• The Key Importance of Screening Underprivileged People in Order to Achieve Global Hepatitis Virus Elimination Targets

  2025cites this paper
• Long‐Term Effects of Direct‐Acting Antivirals on Hepatitis C: Trends in Liver Disease–Related Hospitalisations in Italy

  2025cites this paper
• The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals

  2023cites this paper
• Analysis of mortality and risk of death in HCV- and HCV/HIV-infected patients with extrahepatic manifestations

  2022cites this paper
• Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain

  2022cites this paper
• Study of Prevalence of Autoimmune Manifestations of Chronic Hepatitis C Infection in Beni-Suef Governorate

  2022cites this paper
• Extrahepatic Manifestations of Hepatitis C Virus Infection

  2021cites this paper
• Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C

  2021cites this paper
• Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis

  2021cites this paper
• Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination

  2021cites this paper
• Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents

  2021cites this paper
• Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000–2015): A Nationwide Study

  2020cites this paper
• Epidemiological trend of hepatitis C-related liver events in Spain (2000-2015): A nationwide population-based study.

  2020cites this paper
• Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals

  2020cites this paper
• Mood, immunity and brain connectivity in patients with chronic hepatitis c

  2019cites this paper
• Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.

  2019cites this paper
• Systematic review with meta‐analysis: extrahepatic manifestations in chronic hepatitis C virus‐infected patients in East Asia

  2019cites this paper
• Cryoglobulinemia: An update in 2019.

  2019cites this paper
• Manifestations extrahépatiques secondaires à l’infection chronique par le virus de l’hépatite C

  2019cites this paper
• Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States

  2019cites this paper
• Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients

  2019cites this paper
• [Hepatitis C virus infection, 1989-2019: From discovery to eradication].

  2019cites this paper
• Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection

  2019cites this paper
• Sustained Virologic Response from Interferon-based Hepatitis C regimes IS associated with Reduced risk of Extrahepatic Manifestations.

  2019cites this paper
• One year in review 2019: vasculitis.

  2019cites this paper
• Les cryoglobulinémies

  2019cites this paper
• Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund Data

  2018cites this paper
• Association of C-type lectin 18 levels with extrahepatic manifestations in chronic HCV infection

  2018cites this paper
• The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease

  2018cites this paper
• Family Physicians Can Manage Adults with Hepatitis C.

  2018cites this paper
• Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data

  2018cites this paper
• Economic Burden of Hepatitis C Infection.

  2017cites this paper